Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

Blood

Volumn 118, Issue 25, 2011, Pages 6610-6617

  Ward, Jennifer Ellis ^a   Ren, Ruiyi ^a   Toraldo, Gianluca ^a   SooHoo, Pam ^a   Guan, Jian ^a   O'Hara, Carl ^a   Jasuja, Ravi ^a   Trinkaus Randall, Vickery ^a   Liao, Ronglih ^b   Connors, Lawreen H ^a   Seldin, David C ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN FIBRIL; DOXYCYCLINE; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; IMMUNOGLOBULIN AGGREGATE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE;

EID: 84055223035     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-351643     Document Type: Article

References (50)

1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14)1924-1933.
2. Kisilevsky R. Proteoglycans, glycosaminoglycans, amyloid-enhancing factor, and amyloid deposition. J Intern Med. 1992;232(6):515-516. (Pubitemid 23024322)
3. Pepys MB, Tennent GA, Booth DR, et al. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Ciba Found Symp. 1996;19973-19981.
4. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008-1010. (Pubitemid 38579694)
5. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594-1597. (Pubitemid 32947519)
6. Monis GF, Schultz C, Ren R, et al. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. Am J Pathol. 2006;169(6):1939-1952. (Pubitemid 351181956)
7. Trinkaus-Randall V,Walsh MT, Steeves S, Monis G, Connors LH, Skinner M. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol. 2005;166(1):197-208. (Pubitemid 40051672)
8. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486-489. (Pubitemid 36444329)
9. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A. 2004;101(9):2817-2822. (Pubitemid 38327694)
10. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11(3):213-228. (Pubitemid 38689025)
11. Solomon A, Weiss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol. 1992;140(3):629-637.
12. Hovey BM, Ward JE, Soo Hoo PT, O'Hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis [published online ahead of print May 12, 2011]. Gene Therapy. doi:10.1038/gt.2011.69.
13. Welschof M, Terness P, Kolbinger F, et al. Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J Immunol Methods. 1995;179(2):203-214.
14. Gozal YM, Cheng D, Duong DM, Lah JJ, Levey AI, Peng J. Merger of laser capture microdissection and mass spectrometry: a window into the amyloid plaque proteome. Methods Enzymol. 2006;41277-41293.
15. Klimtchuk ES, Gursky O, Patel RS, et al. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochem. 2010;49(45):9848-9857.
16. Baden EM, Owen BA, Peterson FC, Volkman BF, Ramirez-Alvarado M, Thompson JR. Altered dimer interface decreases stability in an amyloidogenic protein. J Biol Chem. 2008;283(23):15853-15860.
17. Skinner M, Shirahama T, Cohen AS, Deal CL. The association of amyloid P-component (AP) with the amyloid fibril: an updated method for amyloid fibril protein isolation. Prep Biochem. 1982;12(5):461-476. (Pubitemid 13134726)
18. Ren R, Hong Z, Gong H, et al. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J Biol Chem. 2010;285(48):37672-37682.
19. Liao R, Jain M, Cui L, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106(16):2125-2131. (Pubitemid 35192820)
20. Pederson BA, Cope CR, Irimia JM, et al. Mice with elevated muscle glycogen stores do not have improved exercise performance. Biochem Biophys Res Commun. 2005;331(2):491-496. (Pubitemid 40602664)
21. DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81(2):229-236. (Pubitemid 34809348)
22. Holzbaur EL. Motor neurons rely on motor proteins. Trends Cell Biol. 2004;14(5):233-240. (Pubitemid 38591327)
23. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52(4):347-361.
24. Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010;107(9):4188-4193.
25. Prokaeva T, Spencer B, Doros G, Connors LH, Skinner M, Seldin DC. Contribution of light chain variable region genes to organ tropism and survival in AL amyloidosis. Amyloid. 2010;17(S1):62.
26. Ward JE, Brenner D, SooHoo P, et al. Mouse models of AL amyloidosis. In: Skinner M, Berk JL, Connors LH, Seldin DC, eds. XIth International Symposium of Amyloidosis. Boca Raton, FL: Taylor & Francis; 2008:321-323.
27. Marques M, Sarmento JA, Rodrigues S, Guimaraes S, Fonseca E, Macedo G. Gastric amyloidosis: unusual cause of upper gastrointestinal hemorrhage. Endoscopy. 2011;43(suppl 2E):100-101.
28. Shuttleworth E, Keld R, Willert R, Benbow EW. Amyloidosis: an EUS view [published online ahead of print April 4, 2011]. Gastrointest Endosc. doi:10.1016/j.gie.2011.01.039.
29. Khurana R, Gillespie JR, Talapatra A, et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochem. 2001;40(12):3525-3535. (Pubitemid 32242809)
30. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-4959.
31. Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum JN. Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic: a lesson in the generation of transgenic models of disease involving oligomeric proteins. J Biol Chem. 2008;283(4):2098-2107.
32. Maeda S. Mouse models of amyloidoses generated by transgenesis. Amyloid. 1996;3214-3215.
33. Teng M, Buxbaum JN. Transgenic mice in amyloid research: an interpretive review. Amyloid. 1996;3187-3208.
34. Levinson DA, Campos-Torres J, Leder P. Molecular characterization of transgene-induced immunodeficiency in B-less mice using a novel quantitative limiting dilution polymerase chain reaction method. J Exp Med. 1993;178(1):317-329. (Pubitemid 23173267)
35. Baskar JF, Smith PP, Ciment GS, et al. Developmental analysis of the cytomegalovirus enhancer in transgenic animals. J Virol. 1996;70(5):3215-3226. (Pubitemid 26121940)
36. Baskar JF, Smith PP, Nilaver G, et al. The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol. 1996;70(5):3207-3214. (Pubitemid 26121939)
37. Zhan Y, Brady JL, Johnston AM, Lew AM. Predominant transgene expression in exocrine pancreas directed by the CMV promoter. DNA Cell Biol. 2000;19(11):639-645.
38. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411-423. (Pubitemid 47512065)
39. Kyle RA, Kelly JJ, Dyck PJ. Neuropathy Associated with Malignancy: 108: Amyloidosis and Neuropathy. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy (4th ed). Philadelphia, PA: W.B. Saunders; 2005:2427-2451.
40. Fiala JC. Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol. 2007;114(6):551-571. (Pubitemid 50003186)
41. Stokin GB, Goldstein LS. Axonal transport and Alzheimer's disease. Annu Rev Biochem. 2006;75607-75627.
42. Hafezparast M, Klocke R, Ruhrberg C, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science. 2003;300(5620):808-812. (Pubitemid 36532118)
43. Duston MA, Skinner M, Anderson J, Cohen AS. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med. 1989;149(2):358-360. (Pubitemid 19058520)
44. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.
45. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20(2):234-239. (Pubitemid 44933170)
46. Cardoso I, Merlini G, Saraiva MJ. 4′-iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. Faseb J. 2003;17(8):803-809. (Pubitemid 36538654)
47. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001;487(3):404-407. (Pubitemid 32121764)
48. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256-265. (Pubitemid 44294934)
49. Biolo A, Ramamurthy S, Connors LH, et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail. 2008;1(4):249-257.
50. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int. 2005;68(4):1590-1603. (Pubitemid 43169904)